Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Edwin Posadas, MD
With
Epizyme, Inc.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Men electing to undergo radical prostatectomy with preoperative tissue available
Able to take oral medications
Age ≥18 years
Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Adequate organ function
Men with partners of childbearing potential, must have had a successful vasectomy (with medically confirmed lack of sperm that are alive) OR must either practice complete abstinence or agree to use adequate contraception
You may not be if
Active intercurrent illness or malignancy requiring therapy outside of prostate cancer
History of bleeding disorders
Concurrent use of anti-platelet agents or therapeutic anticoagulants with the exception of low-dose aspirin (81 mg daily) or NSAIDs for pain/inflammation.
Concurrent use of strong and moderate CYP3A inhibitors and inducers
Subjects who have previously received tazemetostat
Currently participating in a study using an investigational, medicinal anti-cancer agent within 4 weeks prior to first dose of tazemetostat
